
    
      This is an open label, non-randomized, single-arm continuation protocol study using
      ZEN003694. Patients who have completed participation in their original ("parent") ZEN003694
      protocol and have clinical benefit as determined by the investigator may continue to receive
      treatment with ZEN003694 in the continuation protocol. The patient must have been enrolled in
      a Zenith Epigenetics sponsored ZEN003694 therapeutic study to be eligible for participation
      in this continuation protocol.
    
  